Pharmacological considerations in the modulation of multidrug resistance

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1082-1088

  Fisher, G A ^a   Lum, B L ^a   Hausdorff, J ^a   Sikic, B I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTISENSE OLIGONUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; CYTOTOXIC AGENT; DEXVERAPAMIL; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HORMONE; IFOSFAMIDE; LIPOSOME; NORTAMOXIFEN; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; RAPAMYCIN; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VERAPAMIL DERIVATIVE; VINCA ALKALOID; VINDESINE;

ATAXIA; BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFUSION; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG TRANSPORT; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MULTIDRUG RESISTANCE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0029974821     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00111-6     Document Type: Article

References (69)

1. Pastan I, Gottesman MM. Multi-drug resistance in human cancer. N Engl J Med 1987, 316, 1388-1393.
2. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81, 2215-2222.
3. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993, 60, 157-180.
4. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992, 69, 2603-2609.
5. Nooter K, Herwijer H. Multidrug resistance (MDR) in human cancers. Br J Cancer 1991, 63, 663-669.
6. Roninson IB. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, New York and London, 1991.
7. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-390.
8. Chan H, DeBoer G, Haddad G. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 1995, 9, 275-318.
9. Leighton J, Goldstein L. P-glycoprotein in adult solid tumors: expression and prognostic significance. Hematol Oncol Clin North Am 1995, 9, 251-274.
10. Marie J. P-glycoprotein in adult hematological malignancies. Hematol Oncol Clin North Am 1995, 9, 239-250.
11. Lum B, Gosland M. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995, 9, 319-336.
12. Sugawara I, Kataoka I, Morischita Y. Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988, 48, 4611-4614.
13. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 816, 695-698.
14. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983, 43, 2267-2272.
15. Tamai I, Safa AR. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991, 266, 16796-16800.
16. Naito M, Tsuge H, Kuroko C, et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 1993, 85, 311-316.
17. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonist which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 1992, 43, 2601-2608.
18. Clarke R, Currier S, Kaplan O, et al. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 1992, 84, 1506-1512.
19. Broxterman HJ, Kuiper CM, Schuurhuis GJ. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett 1995, 35, 87-95.
20. Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al. A potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992, 52, 2797-2801.
21. Lehnert M. Reversal of multidrug resistance in breast cancer: many more open questions than answers. Annal Oncol 1993, 4, 11-13.
22. Alquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC, Deeley RG. Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 1995, 55, 102-109.
23. Kruh GD, Gaughan KT, Godwin A, Chan A. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 1995, 87, 1256-1258.
24. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5, 641-647.
25. Kroemer HK, Gautier J, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol 1993, 348, 332-337.
26. Echizen H, Brecht T, Niedergesass S. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 1985, 109, 210-217.
27. HauBermann K, Benz B, Gekeler V. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Pharmacol 1991, 40, 53-59.
28. Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator and dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13, 1985-1994.
29. Motzer R, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995, 13, 1958-1965.
30. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995, 13, 1995-2004.
31. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J. Different modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 1993, 67, 1189-1195.
32. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992, 84, 1811-1816.
33. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992, 28A, 805-810.
34. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 1995, 9, 1631-1637.
35. Yahanda M, Adler KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992, 10, 1624-1634.
36. Gosland M, Brophy N, Duran G. Bilirubin: a physiological substrate for the multidrug transporter. Proc Am Assoc Cancer Res 1991, 32, 426.
37. Thalhammer T, Swatonek H, Riegler S, Gajdzk L, Graf J. Selective inhibition of hepatic P-glycoprotein mediated excretion by SDZ PSC 833 and dexniguldipine. Anti-cancer Drugs 1994, 5, S1, 16-36.
38. Vickers AEM, Meyer E, Dannecker R, Keller B, Tynes RE, Maurer G. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. Am Soc Pharmacol Exp Ther 1995, 23, 321-326.
39. Boote D, Dennis I, Twentyman P, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996, 14, 610-618.
40. Hausdorff J, Fisher GA, Halsey J, et al. A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc Am Soc Clin Oncol 1995, 14, 181-407.
41. Collins HL, Fisher GA, Hausdorff J, et al. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resist-ance modulator. Proc Am Soc Clin Oncol 1995, 14, 181-406.
42. Hausdorff J, Fisher GA, Lum BL, Halsey J, Mallarino MC, Sikic BI. Doxorubicin, paclitaxel, and oral PSC 833, a modulator of multidrug resistance: a phase I trial. Proc Am Soc Clin Oncol 1996, 15, 397 (abstract).
43. Thalhammer T, Stapf V, Gajdzik L, Graf J. Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur J Pharmacol 1994, 270, 213-220.
44. Dutt A, Priebe T, Teeter L. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 1992, 261, 1222-1230.
45. Zacherl J, Hamilton G, Thalhammer T, et al. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol 1994, 34, 125-132.
46. Tatsuta T, Naito M, Oh-hara T, Sugawara T, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992, 267, 20383-20391.
47. Borst P, Schinkel AH, Smit JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993, 60, 289-299.
48. Schinkel AH, Mol CAAM, Wagenaar E, Van Deemter L, Smit JJM, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A, 7/8, 1295-1298.
49. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdrla P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
50. Garcia Del Moral R, O'Valle F, Andujar M, et al. Relationship between P-glycoprotein expression and cyclosporin A in kidney. Am J Pathol 1995, 146, 398-408.
51. Vollrath V, Wielandt AM, Acuna C, Duarte I, Andrade L, Chianale J. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol 1994, 21, 754-763.
52. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, Thorgeirsson SS. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology 1993, 17, 854-860.
53. Berg SL, Tocher A, O'Shaughnessy JA, et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995, 13, 2039-2042.
54. Ukena D, Boewer C, Oldenkott B, et al. Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial. Cancer Chem Pharmacol 1995, 36, 160-164.
55. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-92.
56. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994, 12, 835-842.
57. Yuen A, Sikic B, Horning S. Phase II trial of Oncep chemotherapy in patients with relapsed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1995, 14, 392.
58. Ferguson LR, Baguley BC. Multidrug resistance and mutagenesis. Mutation Res 1993, 225, 79-90.
59. Sikic B. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11, 1629-1635.
60. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. Cancer 1993, 72, 3502-3514.
61. Kerr DJ, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986, 18, 239-242.
62. Mross K, Hamm K, Hossfeld DK. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 1993, 31, 369-375.
63. Millward MJ, Cantwell BMJ, Lien EA, et al. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992, 28A, 805-810.
64. Fedeli L, Clozza M, Boschetti E, et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989, 64, 1805-1811.
65. Philip PA, Joel S, Monkman SC, et al. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 1992, 65, 267-270.
66. Lum BL, Kaubisch S, Fisher GA, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10, 1635-1642.
67. Fisher GA, Hausdorff J, Lum BL, et al. Phase I trial of etoposide with cyclosporine SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 1994, 13, 43.
68. Erlichman C, Moore M, Thiessen J, et al. A phase I trial of doxorubicin (D) and PSC833, a modulator of multidrug resist-ance (MDR). Proc Am Soc Clin Oncol 1994, 13, 134.
69. Giaccone G, Linn SC, Catimel G, et al. Phase I and pharmacokinetic study of SDZ PSC 833 per os in combination with doxorubicin in patients with solid tumors. Proc Am Soc Clin Oncol 1994, 13, 142.